Angeliq is owned by Bayer Hlthcare.
Angeliq contains Drospirenone; Estradiol.
Angeliq has a total of 1 drug patent out of which 0 drug patents have expired.
Angeliq was authorised for market use on 28 September, 2005.
Angeliq is available in tablet;oral dosage forms.
The generics of Angeliq are possible to be released after 22 October, 2031.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8906890||BAYER HLTHCARE||Very low-dosed solid oral dosage forms for HRT|| |
(8 years from now)
Market Authorisation Date: 28 September, 2005
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic